Renalytix AI PLC ADR (RNLX) News
Filter RNLX News Items
RNLX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest RNLX News From Around the Web
Below are the latest news stories about RENALYTIX PLC that investors may wish to consider to help them evaluate RNLX as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayIt's time to start Tuesday trading with a breakdown of the biggest pre-market stock movers worth keeping an eye on this morning! |
Renalytix Reports Financial Results for First Quarter of Fiscal Year 2024LONDON and SALT LAKE CITY, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today reported financial results for the fiscal first quarter ended September 30, 2023. Recent Highlights (including post period events) Financing discussions in process with goal to provide operating runway |
Renalytix to Report Financial Results for First Quarter Fiscal Year 2024 on November 14LONDON and SALT LAKE CITY, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that it will report its first quarter fiscal year 2024 financial results on Tuesday, November 14, 2023, before market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (GMT). Conference Call Detail |
What Makes Renalytix AI PLC Sponsored ADR (RNLX) a New Strong Buy StockRenalytix AI PLC Sponsored ADR (RNLX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
US Patent Office Allows Patent Claims for Intellectual Property Exclusively Licensed to RenalytixLONDON and SALT LAKE CITY, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), the first company to commercialize an FDA authorized artificial intelligence (AI) enabled blood test to assess risk of progressive kidney function decline for individuals with type 2 diabetes and early-stage chronic kidney disease, announces that the US Patent Office has issued a new notice of allowance of claims surrounding the biomarkers sTNFR1 and sTNFR2 used in the kidneyintelX.dkd test. Th |
Renalytix AI PLC Sponsored ADR (RNLX) Loses -44.61% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerRenalytix AI PLC Sponsored ADR (RNLX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayPre-market stock movers are a major topic this morning as we check out the biggest ones worth keeping an eye on for Tuesday! |
Renalytix Plc (NASDAQ:RNLX) Q4 2023 Earnings Call TranscriptRenalytix Plc (NASDAQ:RNLX) Q4 2023 Earnings Call Transcript September 29, 2023 Operator: Good morning, and welcome to the Renalytix Conference Call to Review Fourth Quarter and Full-Year Fiscal 2023 Financial Results. At this time, all participants are in a listen-only mode. We will be facilitating a question-and-answer session towards the end of today’s call. As […] |
Renalytix to Report Financial Results for Fourth Quarter and Full Year Fiscal 2023 on September 28LONDON and SALT LAKE CITY, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) will report its fourth quarter and full year fiscal 2023 financial results on Thursday, September 28, 2023, before market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (BST). Conference Call Details:To |
Renalytix Appoints Senior Executive Howard Doran as Chief Business OfficerDoran Brings Significant Diagnostics Sector Experience to Lead the KidneyIntelX Global Sales EffortLONDON and SALT LAKE CITY, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), the first company to commercialize an FDA approved artificial intelligence (AI) enabled prognostic blood test for individuals with type 2 diabetes and chronic kidney disease, announces the appointment of Howard Doran as Chief Business Officer, effective September 1, 2023. Mr. Doran’s primary resp |